{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:32:37Z","timestamp":1790735557716,"version":"4.1.0"},"reference-count":151,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:p>In rare cases, bisphosphonates are well established to cause ocular inflammation, presenting as uveitis, episcleritis, scleritis, orbital inflammation, and\/or conjunctivitis. Some reports of bisphosphonate-associated neuro-ophthalmic complications also exist. We identified 101 reports in the literature relating to bisphosphonate-associated ocular complications. In a great majority of cases, symptoms resolve after discontinuation of the drug and anti-inflammatory treatment. Many cases recur if rechallenged with the same bisphosphonate. First-generation nonamino bisphosphonates, including clodronate and etidronate, are not associated with ocular inflammation. Only 2nd- and 3rd-generation amino bisphosphonates, including pamidronate, alendronate, risedronate, ibandronate, and zoledronate are associated with these complications. The mechanism of bisphosphonate-induced ocular inflammation may be related to activation of \u03b3\/\u03b4 T cells or M1 macrophages. Intravenous forms, such as pamidronate and zoledronate, tend to have higher rates and faster onset of ocular inflammation, generally presenting within days of infusion. In oral bisphosphonates, such as alendronate and risedronate, these complications present with more sporadic timing. Rates of complications are also higher when bisphosphonates are used for malignancy, as doses tend to be higher compared with doses for osteoporosis.<\/jats:p>","DOI":"10.1089\/jop.2022.0094","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T11:46:05Z","timestamp":1669031165000},"page":"3-16","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":40,"title":["Ocular Side Effects of Bisphosphonates: A Review of Literature"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2388-7770","authenticated-orcid":false,"given":"Nicholas A.","family":"Chartrand","sequence":"first","affiliation":[{"name":"College of Medicine Phoenix, University of Arizona, Phoenix, Arizona, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3705-8252","authenticated-orcid":false,"given":"Chap-Kay","family":"Lau","sequence":"additional","affiliation":[{"name":"College of Medicine Phoenix, University of Arizona, Phoenix, Arizona, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5490-226X","authenticated-orcid":false,"given":"Mark T.","family":"Parsons","sequence":"additional","affiliation":[{"name":"College of Medicine Phoenix, University of Arizona, Phoenix, Arizona, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0671-8171","authenticated-orcid":false,"given":"Jaiden J.","family":"Handlon","sequence":"additional","affiliation":[{"name":"Hoopes Vision Research Center, Hoopes Vision, Draper, Utah, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8852-4380","authenticated-orcid":false,"given":"Yasmyne C.","family":"Ronquillo","sequence":"additional","affiliation":[{"name":"Hoopes Vision Research Center, Hoopes Vision, Draper, Utah, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip C.","family":"Hoopes","sequence":"additional","affiliation":[{"name":"Hoopes Vision Research Center, Hoopes Vision, Draper, Utah, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1024-6250","authenticated-orcid":false,"given":"Majid","family":"Moshirfar","sequence":"additional","affiliation":[{"name":"Hoopes Vision Research Center, Hoopes Vision, Draper, Utah, USA."},{"name":"Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City, Utah, USA."},{"name":"Utah Lions Eye Bank, Murray, Utah, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2269"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2565"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2405"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1592367"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351403"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1226"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067312"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)72902-2"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.111752"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1783"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31816576ef"},{"issue":"1","key":"e_1_3_3_14_2","first-page":"54","article-title":"Possible ocular adverse effects attributable to bisphosphonate therapy: Two case reports","volume":"24","author":"G\u00f3mez Escobar LG","year":"2017","unstructured":"G\u00f3mez Escobar LG, , Gonz\u00e1lez Devia D. Possible ocular adverse effects attributable to bisphosphonate therapy: Two case reports. Rev Colomb Reumatol, 2017; 24(1):54\u201359; doi: 10.1016\/j.rcreu.2016.06.002","journal-title":"Rev Colomb Reumatol"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-021-00964-z"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60752-0"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152012799014959"},{"key":"e_1_3_3_18_2","unstructured":"Ganesan K Goyal A Roane D. Bisphosphonate. Treasure Island Florida: StatPearls; 2022."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.4.378"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13867"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X14566424"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.5693\/djo.02.2017.08.002"},{"key":"e_1_3_3_23_2","article-title":"Drug-induced ocular side effects","author":"Fraunfelder F","year":"2021","unstructured":"Fraunfelder F, , Fraunfelder F. Drug-induced ocular side effects. Clin Ocul Toxicol, 2021; iii; doi: 10.1016\/b978-0-323-65375-6.01001-x","journal-title":"Clin Ocul Toxicol"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e31829f3b46"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031323"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12910"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1613-0"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00614"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-018-0074-9"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201801791RR"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.852297"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.25002\/tji.2020.1261"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.11.006"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/375155a0"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.384.013k07_384_392"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903043400914"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328335729c"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.39732"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32801094b5"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40048"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1328337"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01840-8"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)93029-Z"},{"key":"e_1_3_3_44_2","doi-asserted-by":"crossref","unstructured":"Fraunfelder F \u201cFritz\u201d T and Fraunfelder F \u201cRick\u201d W. Heavy Metal Antagonists and Miscellaneous Drugs. In: Drug-Induced Ocular Side Effects. London UK: Elsevier; 2021; pp. 361\u2013406; doi: 10.1016\/b978-0-323-65375-6.00016-5","DOI":"10.1016\/B978-0-323-65375-6.00016-5"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.12.052"},{"issue":"10","key":"e_1_3_3_46_2","first-page":"1015","article-title":"Ocular side effects of bisphosphonates a case report and literature review","volume":"56","author":"Mckague M","year":"2010","unstructured":"Mckague M, , Ccfp M, , Jorgenson D, et al. Ocular side effects of bisphosphonates a case report and literature review. Can Fam Physician, 2010; 56(10):1015\u20131017.","journal-title":"Can Fam Physician"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v17i1.10176"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.028"},{"key":"e_1_3_3_49_2","first-page":"110","article-title":"acid","volume":"65","author":"Chatterjee S","year":"2017","unstructured":"Chatterjee S, , Agrawal D. Bilateral acute anterior uveitis and conjunctivitis following intravenous zoledronic acid. J Assoc Physicians India, 65:110\u2013111, 2017.","journal-title":"J Assoc Physicians India"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X20944305"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1745245"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afy070"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273940902916111"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2012.03.020"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2017.0018"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2008.tb01658.x"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701461"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.4921"},{"key":"e_1_3_3_59_2","article-title":"Bisphosphonates related ocular side effects: A case series and review of literature","author":"Gendelman O","year":"2021","unstructured":"Gendelman O, , Tripto - Shkolnik L, , Vered I, et al. Bisphosphonates related ocular side effects: A case series and review of literature. Ocul Immunol Inflamm, 2021; doi: 10.1080\/09273948.2021.1922705","journal-title":"Ocul Immunol Inflamm"},{"key":"e_1_3_3_60_2","first-page":"91","article-title":"Zoledronate-induced anterior uveitis, scleritis and optic neuritis: A case report","volume":"134","author":"Wolpert LE","year":"2021","unstructured":"Wolpert LE, , Watts AR. Zoledronate-induced anterior uveitis, scleritis and optic neuritis: A case report. N Z Med J, 2021; 134:91\u201394.","journal-title":"N Z Med J"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-0926-x"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-5-156"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-007-9006-2"},{"key":"e_1_3_3_64_2","first-page":"355","volume-title":"Ginecol Obstet Mex","author":"Albani-Campanario M","year":"2012","unstructured":"Albani-Campanario M, , Buend\u00eda-D\u00edaz G, , Flores-Islas M de L, et al. [Zoledronic Acid-Based Uveitis: A Case Report and a Bibliography Review]. Ginecol Obstet Mex, 2012; 80:355\u2013359."},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2006.04.013"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1654_19"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2008.04.005"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14063"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080273"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.3109\/08820538.2013.839806"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.4103\/0974-620X.53046"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2872-5"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02238770"},{"key":"e_1_3_3_74_2","unstructured":"Lespagnard S Bonnet S Betz P. [Clinical Case of the Month. Bilateral Optic Neuropathy Secondary to Biphosphonate Therapy]. Rev Med Liege n.d.;65(7\u20138):434\u2013436."},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1258\/rsmsmj.55.2.58k"},{"key":"e_1_3_3_76_2","first-page":"35","article-title":"Ibandronate (Boniva): A New Oral Bisphosphonate","volume":"47","author":"Anonymous","year":"2005","unstructured":"Anonymous. Ibandronate (Boniva): A New Oral Bisphosphonate. Med Lett Drugs Ther, 2005; 47:35.","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2015.04.006"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200421140-00005"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.3129\/i09-110"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12263"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S22429"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155208097632"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000225713.00630.e5"},{"key":"e_1_3_3_84_2","first-page":"71","article-title":"Posterior Uveitis: An under-recognized adverse effect of pamidronate: 2 Case Reports","volume":"290","author":"Haverbeke G","year":"2003","unstructured":"Haverbeke G, , Pertile G, , Claes C, et al. Posterior Uveitis: An under-recognized adverse effect of pamidronate: 2 Case Reports. Bull Soc Belge Ophtalmol, 2003; 290:71\u201376.","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.4321\/S0365-66912004000200009"},{"key":"e_1_3_3_86_2","first-page":"U1888","article-title":"Drug-induced optic neuritis and uveitis secondary to bisphosphonates","volume":"119","author":"Stack R","year":"2006","unstructured":"Stack R, , Tarr K. Drug-induced optic neuritis and uveitis secondary to bisphosphonates. N Z Med J, 2006; 119:U1888.","journal-title":"N Z Med J"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.1995.tb09976.x"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2035-z"},{"key":"e_1_3_3_89_2","first-page":"23","article-title":"Orbital Inflammation after Use of zoledronic acid for metastasized prostate carcinoma","volume":"315","author":"Missotten G","year":"2010","unstructured":"Missotten G, , Verheezen Y. Orbital Inflammation after Use of zoledronic acid for metastasized prostate carcinoma. Bull Soc Belge Ophtalmol, 2010; 315:23\u201324.","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7753(02)72464-0"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7753(05)72150-3"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6700542"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2012.12.006"},{"issue":"5","key":"e_1_3_3_94_2","first-page":"365","article-title":"Scleritis Related to the Use of Bisphosphonates","volume":"46","author":"de Almeida PJA.","year":"2006","unstructured":"Passos \u00c2F, de Almeida PJA. Scleritis Related to the Use of Bisphosphonates. Rev Bras Reumatol, 2006; 46(5):365\u2013368; doi: 10.1590\/s0482-50042006000500013","journal-title":"Rev Bras Reumatol"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1996.tb01932.x"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.053"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-303355"},{"issue":"1","key":"e_1_3_3_98_2","first-page":"177","article-title":"The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and\/or bevacizumab","volume":"28","author":"Papadopoulou E","year":"2020","unstructured":"Papadopoulou E, , Nicolatou-Galitis O, , Papassotiriou I, et al. The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and\/or bevacizumab. Support Care Cancer, 2020; 28(1):177\u2013184; doi: 10.1007\/s00520-019-04793-2","journal-title":"Support Care Cancer"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.09.035"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-303007"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/206837"},{"key":"e_1_3_3_102_2","first-page":"44","article-title":"Safety of intravitreal zoledronic acid, an anti-angiogenic bisphosphonate, in a rat model","volume":"9","author":"Nourinia R","year":"2014","unstructured":"Nourinia R, , Ahmadieh H, , Rezaei-Kanavi M, et al. Safety of intravitreal zoledronic acid, an anti-angiogenic bisphosphonate, in a rat model. J Ophthalmic Vis Res, 2014; 9:44\u201349.","journal-title":"J Ophthalmic Vis Res"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1413347112"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpc.2020.106430"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.04.022"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13589"},{"key":"e_1_3_3_107_2","unstructured":"Cavallasca JA Reyt C. [Acute Anterior Uveitis Associated with the Use Zoledronic Acid]. Medicina (B Aires) 2014; 74:428\u2013429."},{"issue":"2","key":"e_1_3_3_108_2","first-page":"e106","article-title":"Orbital pseudotumor in a patient treated with zoledronic acid: A case report and pertinent literature review","volume":"2","author":"Manuylova E","year":"2016","unstructured":"Manuylova E, , Clark N, , Shafiq I. Orbital pseudotumor in a patient treated with zoledronic acid: A case report and pertinent literature review. AACE Clin Case Rep, 2016; 2(2):e106\u2013e109; doi: 10.4158\/EP15699.CR","journal-title":"AACE Clin Case Rep"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32831c8adc"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1024\/1661-8157\/a002878"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-017-0538-3"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6647277"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-245359"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.3109\/01676830.2015.1078380"},{"issue":"2","key":"e_1_3_3_115_2","first-page":"134","article-title":"A case series and review of bisphosphonate-associated orbital inflammation","volume":"24","author":"Lefebvre DR","year":"2016","unstructured":"Lefebvre DR, , Mandeville JT, , Yonekawa Y, et al. A case series and review of bisphosphonate-associated orbital inflammation. Ocul Immunol Inflamm, 2016; 24(2):134\u2013139; doi: 10.3109\/09273948.2014.942747","journal-title":"Ocul Immunol Inflamm"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-019-04850-w"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-019-1063-8"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.3109\/01676830.2011.648818"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13659"},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218785967"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP11081.CR"},{"key":"e_1_3_3_122_2","first-page":"50","article-title":"Zolendronate associated inflammatory orbital disease","volume":"123","author":"Yeo J","year":"2010","unstructured":"Yeo J, , Jafer AK. Zolendronate associated inflammatory orbital disease. N Z Med J, 2010; 123:50\u201352.","journal-title":"N Z Med J"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2012.09.011"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0b013e3181c1a589"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000433"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.3109\/01676830.2010.535641"},{"key":"e_1_3_3_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.09.041"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-1048-1"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2007.17"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2021.04.655"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21822"},{"key":"e_1_3_3_132_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0803366"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2017.06.048"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000055"},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1994.tb02186.x"},{"key":"e_1_3_3_136_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.5.479"},{"key":"e_1_3_3_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1169-8330(00)80008-3"},{"key":"e_1_3_3_138_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2007.0046"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.8.956"},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.9.1335"},{"key":"e_1_3_3_141_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.12.1443"},{"key":"e_1_3_3_142_2","first-page":"49","article-title":"Nongranulomatous anterior uveitis associated with alendronate therapy","volume":"43","author":"Salmen S","year":"2002","unstructured":"Salmen S, , Berrueta L, , S\u00e1nchez N, et al. Nongranulomatous anterior uveitis associated with alendronate therapy. Invest Clin, 2002; 43:49\u201352.","journal-title":"Invest Clin"},{"key":"e_1_3_3_143_2","doi-asserted-by":"publisher","DOI":"10.1159\/000202646"},{"issue":"12","key":"e_1_3_3_144_2","first-page":"e12024","article-title":"Bisphosphonate-induced acute orbital inflammation in a patient with underlying thyroid ophthalmopathy","volume":"12","author":"Yu J","year":"2020","unstructured":"Yu J, , Guan J. Bisphosphonate-induced acute orbital inflammation in a patient with underlying thyroid ophthalmopathy. Cureus, 2020; 12(12):e12024; doi: 10.7759\/cureus.12024","journal-title":"Cureus"},{"key":"e_1_3_3_145_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.SMJ.0000152753.80490.9F"},{"key":"e_1_3_3_146_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273940802056281"},{"key":"e_1_3_3_147_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2019.01.007"},{"key":"e_1_3_3_148_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20213210S1136d"},{"issue":"1","key":"e_1_3_3_149_2","first-page":"S269","article-title":"Bilateral acute anterior uveitis after oral risedronate administration","volume":"28","author":"Dumitru A.M.","year":"2017","unstructured":"Dumitru A.M., , Dragomir AS, , Taujan GC, et al. Bilateral acute anterior uveitis after oral risedronate administration. Osteoporos Int, 2017; 28(S1):S269; doi: 10.1007\/s00198-017-3950-2","journal-title":"Osteoporos Int"},{"key":"e_1_3_3_150_2","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.37525"},{"key":"e_1_3_3_151_2","first-page":"639","article-title":"[Ocular Myasthenia Revealed by Risedronate]","volume":"55","author":"Sanchez-Ayaso PA","year":"2012","unstructured":"Sanchez-Ayaso PA, , Garcia-Munozguren S, , Salmeron MP. [Ocular Myasthenia Revealed by Risedronate]. Rev Neurol, 2012; 55:639\u2013640.","journal-title":"Rev Neurol"},{"key":"e_1_3_3_152_2","first-page":"251","article-title":"R\u0131sedronata Ba\u011fli Gel\u0131\u015fen Nad\u0131r B\u0131r Yan Etk\u0131; Konjunkt\u0131v\u0131t: Olgu Sunumu","volume":"18","author":"\u00d6zt\u00fcrk G","year":"2015","unstructured":"\u00d6zt\u00fcrk G, , Aydo\u011f E, , Geler K\u00fclc\u00fc D. R\u0131sedronata Ba\u011fli Gel\u0131\u015fen Nad\u0131r B\u0131r Yan Etk\u0131; Konjunkt\u0131v\u0131t: Olgu Sunumu. Turk Geriatri Derg, 2015; 18:251\u2013254.","journal-title":"Turk Geriatri Derg"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2022.0094","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2022.0094","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2022.0094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:45:19Z","timestamp":1777646719000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2022.0094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":151,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2,1]]}},"alternative-id":["10.1089\/jop.2022.0094"],"URL":"https:\/\/doi.org\/10.1089\/jop.2022.0094","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]}}}